immunotherapy

Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)

Media ReleaseCOPENHAGEN, Denmark; December 7, 2024 Results show 96 percent overall response rate (ORR), 87 percent complete response (CR), and…

2 weeks ago

Y-mAbs Presents SADA Platform Preclinical Data and Trial in Progress Posters at the 2024 American Society Hematology (ASH) Annual Meeting

NEW YORK, Dec. 07, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical…

2 weeks ago

ITRI to Exhibit Innovations in Wellness and Smart Medical Tech at CES 2025

HSINCHU, Dec. 6, 2024 /PRNewswire/ -- The Industrial Technology Research Institute (ITRI), Taiwan's largest and one of the world's leading high-tech…

3 weeks ago

Theriva™ Biologics Announces U.S. FDA Guidance on Design of Phase 3 Study of VCN-01 for the Treatment of Metastatic Pancreatic Cancer

ROCKVILLE, Md., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed…

3 weeks ago

Medicenna Provides Clinical Update and Announces First Complete Responder in MDNA11 and KEYTRUDA® (pembrolizumab) Combination Dose Escalation Arm of the ABILITY-1 Study

70-year-old patient with advanced chemo-refractory anal cancer achieves complete response (CR) in 8 weeks when treated with MDNA11 in combination…

3 weeks ago

Pompano Veterinary Oncology Partners with Sensus Healthcare to Provide First Superficial Radiotherapy Services in a Mobile Configuration

Full-service medical oncology practice to pioneer the use of SRT to treat companion animals for both home and veterinary clinic…

3 weeks ago

Coeptis Therapeutics Executes Binding Letter of Intent to Acquire Ai-powered Marketing Solutions for Biotech, Pharmaceutical and Other Industries

The Acquisition of NexGenAI Affiliates Network Expands Company's Capabilities and Drives Innovation, Operational Efficiency, and Opportunity for Growth WEXFORD, Pa. ,…

3 weeks ago

Enlivex Announces Positive Interim Efficacy Data from Allocetra Trial in Patients with Moderate to Severe Knee Osteoarthritis

Nes-Ziona, Israel, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy…

3 weeks ago

Lisata Therapeutics and Kuva Labs Announce Global License Agreement for Solid Tumor Imaging

License provides Lisata’s innovative certepetide targeting agent for use with Kuva’s NanoMark™ MR imaging platform to advance non-invasive, high-precision cancer…

3 weeks ago

Elevar Therapeutics and Relay Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors

Global licensing agreement grants Elevar Therapeutics worldwide rights to develop and commercialize lirafugratinib (RLY-4008) Lirafugratinib is a potential best-in-class FGFR2…

3 weeks ago